Abstract
Decarboxylation, reduction and hydrolysis can yield active metabolites from the parent drug. Major therapeutic indications and metabolic routes of these drugs are reviewed.
Changes in the logP values (determined and calculated) from the parent drug to the active metabolite show certain characteristics in comparison to other phase I metabolic alterations. Metabolic decarboxylation of parent drug is commonly associated with increase in lipophilicity. However, in some cases, decarboxylation may cause a reduction in lipophilicity. Ester hydrolysis generally unmasks either the polar carboxylic or hydroxyl group with the outcome of an increase in hydrophilicity. On the contrary, hydrolysis of phosphate ester means a huge increase in the lipophilic character of the drug, as the highly polar phosphate group is removed.
Keywords: Active metabolites, metabolic decarboxylation, metabolic reduction and metabolic hydrolysis, Parent Drugs, Idarubicin, Prontosil, lipophilicity, half-life
Current Drug Metabolism
Title:Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Volume: 13 Issue: 6
Author(s): I. Hartyanszky, H. Kalasz, E. Adeghate, Zs. Gulyas, M. Y. Hasan, K. Tekes, A. Adem and P. Sotonyi
Affiliation:
Keywords: Active metabolites, metabolic decarboxylation, metabolic reduction and metabolic hydrolysis, Parent Drugs, Idarubicin, Prontosil, lipophilicity, half-life
Abstract: Decarboxylation, reduction and hydrolysis can yield active metabolites from the parent drug. Major therapeutic indications and metabolic routes of these drugs are reviewed.
Changes in the logP values (determined and calculated) from the parent drug to the active metabolite show certain characteristics in comparison to other phase I metabolic alterations. Metabolic decarboxylation of parent drug is commonly associated with increase in lipophilicity. However, in some cases, decarboxylation may cause a reduction in lipophilicity. Ester hydrolysis generally unmasks either the polar carboxylic or hydroxyl group with the outcome of an increase in hydrophilicity. On the contrary, hydrolysis of phosphate ester means a huge increase in the lipophilic character of the drug, as the highly polar phosphate group is removed.
Export Options
About this article
Cite this article as:
Hartyanszky I., Kalasz H., Adeghate E., Gulyas Zs., Y. Hasan M., Tekes K., Adem A. and Sotonyi P., Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs, Current Drug Metabolism 2012; 13 (6) . https://dx.doi.org/10.2174/138920012800840437
DOI https://dx.doi.org/10.2174/138920012800840437 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Interaction between drugs and endocrine diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Tissue Distribution and Metabolism of Micro- and Nanoparticles and Medical Implants
With the continuous advancement of modern science and engineering, numerous functional materials and active molecules have been developed and utilized in various industrial, medical, and food applications. Many of these can enter the body, either actively or passively, and have significant and intricate impacts on human health. For example, biomaterials ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews New Developments in Antimicrobial Use in Sepsis
Current Pharmaceutical Design Infection and Hemodialysis Access: An Updated Review.
Infectious Disorders - Drug Targets Cardiovascular Diseases in Pregnancy - A Brief Overview
Current Cardiology Reviews Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design Antibiotic Use in Children - Off-Label Use
Current Drug Targets Emergence of Multi-Drug Resistance Gram-Positive Bacteria and New Active Antibiotics
Current Medicinal Chemistry - Anti-Infective Agents Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design Chlorophylls and their Derivatives Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Glycoprotein Targeting and Other Applications of Lectins in Biotechnology
Current Protein & Peptide Science Endophthalmitis
Anti-Infective Agents in Medicinal Chemistry Production and Application of Bacteriophage and Bacteriophage-Encoded Lysins
Recent Patents on Biotechnology Myocardial Infarction in Systemic Lupus Erythematosus – the Sex-Specific Risk Profile
Current Pharmaceutical Design Drainage of Cerebral Abscesses Prior to Valve Replacement in Stable Patients with Acute Left-Sided Infective Endocarditis
CNS & Neurological Disorders - Drug Targets Development and Validation of A Stability-Indicating Mekc Method for Determination of Flucloxacillin Sodium in Capsules
Current Analytical Chemistry Non-Microbicidal Control of Bacterial Biofilms with Small Molecules
Anti-Infective Agents Point of Care Cardiac Ultrasound Applications in the Emergency Department and Intensive Care Unit - A Review
Current Cardiology Reviews Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets Nitric Oxide: A Key Mediator of Biofilm Dispersal with Applications in Infectious Diseases
Current Pharmaceutical Design Ischemic Strokes in Congenital Bleeding Disorders: Comparison with Myocardial Infarction and other Acute Coronary Syndromes
Cardiovascular & Hematological Disorders-Drug Targets